Vaishali Pharma Limited (NSE:VAISHALI)
India
· Delayed Price · Currency is INR | Market Cap | 849.31M |
| Revenue (ttm) | 1.14B |
| Net Income (ttm) | -5.09M |
| Shares Out | 130.46M |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,225 |
| Average Volume | 166,869 |
| Open | 6.78 |
| Previous Close | 6.51 |
| Day's Range | 6.53 - 6.78 |
| 52-Week Range | 6.40 - 15.24 |
| Beta | -0.36 |
| RSI | 21.35 |
| Earnings Date | Feb 13, 2026 |
About Vaishali Pharma
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, anti–malarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-viral, anti-epileptic, anti-asthmatic, enzymes, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helminitic. The company also provides... [Read more]
Financial Performance
In fiscal year 2025, Vaishali Pharma's revenue was 990.26 million, an increase of 14.77% compared to the previous year's 862.80 million. Earnings were 8.17 million, an increase of 13.70%.
Financial StatementsNews
Vaishali Pharma shares surge 3% after company plans on ambitious growth strategy
Vaishali Pharma shares jumped more than 3% after the company announced a board meeting on October 3, 2024, to discuss potential mergers and acquisitions to strengthen its roots and extend its product ...
Vaishali Pharma to explore merger and acquisition strategy in upcoming board meeting on October 3
Vaishali Pharma Limited has announced a board meeting on October 3, 2024, to discuss strategic mergers and acquisitions aimed at deepening its roots and expanding its product portfolio. The pharmaceut...
Vaishali Pharma Ltd (NSE:VAISHALI) Q3 2024 Earnings Call Transcript Highlights: Strong ...
Vaishali Pharma Ltd (NSE:VAISHALI) Q3 2024 Earnings Call Transcript Highlights: Strong Financial Performance and Strategic Growth Plans